Sefaxersen (RO7434656)

Phase 3Small molecule

Sefaxersen (RO7434656) is one of 2 small molecule programs targeting Primary IgA Nephropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Iga NephropathyActive, not recruiting

Primary Iga NephropathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Primary Iga Nephropathy

#DrugCompanyPhaseTrials

LNP023

Novartis

Phase 3

1 2

Sefaxersen (RO7434656)

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Active, not recruiting

Primary Iga Nephropathy

NCT05797610

Clinical

Trials by Indication[1]

Primary IgA Nephropathy1 trial

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05797610·459 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sefaxersen (RO7434656). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sefaxersen (RO7434656) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sefaxersen (RO7434656). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Sefaxersen (RO7434656)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Primary IgA Nephropathy1 trial

References

Drug Info

Quick Facts

Related News